|Videos|August 4, 2021
Integrated Early Phase to Commercial Drug Substance to Drug Product
Author(s)Lonza
In this 15-minute talk, David K. Lyon, PhD, Senior Fellow of Research, Lonza, discusses a flexible, integrated model supporting over 600 small molecule therapies.
Related Content
Trending on Pharmaceutical Technology
1
Europe Tried to Ban Generative AI From Critical GMP. The Ban May Not Survive. It Does Not Matter.
2
Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem
3
What Does TAUKLARIFY's Approval Mean for Alzheimer's Drug Developers?
4
Engineering High-Speed Pen Injector Pre-Assembly Machine: Overcoming Dimensional Variability in Multi-Component Mechanism Integration
5